Search Results

You are looking at 1 - 10 of 87 items for :

  • "rituximab" x
Clear All
Authors: Valentin Brodszky, László Czirják, Pál Géher, László Hodinka, Krisztián Kárpáti, Márta Péntek, Gyula Poór, Zoltán Szekanecz and László Gulácsi

–255. EMEA: Mabthera: Alkalmazási előirat. EMEA, 2006. Cohen, S. B., Emery, P., Greenwald, M. W. és mtsai: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a

Restricted access
Authors: Zsófia Simon, Árpád Illés, Zsófia Miltényi, Ferenc Magyari, László Váróczy, Nikolett Péter and Lajos Gergely

Abulayha, A. M., Tabal, S. A., Shawesh, E. I., et al.: Depletion of peripheral blood B cells with rituximab and phenotype characterization of the recovering population in a patient with follicular

Restricted access

fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2009, 27 , 498–503. Land S. R

Restricted access

Abstract  

Rituximab was successively labeled with [67Ga]-gallium chloride after residulation with freshly prepared cyclic DTPA-dianhydride. The best results of the conjugation were obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH 8) to a glass tube pre-coated with DTPA-dianhydride (0.01 mg) at 25 °C with continuous mild stirring for 30 minutes. Radio thin-layer chromatography showed an overall radiochemical purity of 96–99% at optimized conditions (specific activity = 300–500 MBq/mg, labeling efficiency 77%). The final isotonic 67Ga-DTPA-rituximab complex was checked by gel electrophoresis for radiolysis control. Radio-TLC was performed to ensure the formation of only one species, followed by filtration through a 0.22 μm filter. Preliminary in vivo studies in normal rat model was performed to determine the biodistribution of the radioimmunoconjugate up to 6 hours.

Restricted access
Authors: Tamás Schneider, Zsuzsanna Molnár, Beáta Deák, Erika Várady, Erika Tóth, Judit Csomor, András Matolcsy, József Lővey, Zsolt Lengyel, Klára Petri, István Gaudi and András Rosta

Coiffier, B., Lepage, E., Briere, J. és mtsai: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 2002, 346 , 235–242. Briere J

Open access
Authors: Tamás Schneider, Erika Tóth, József Lővey, Zsuzsanna Molnár, Beáta Deák, Erika Várady, Judit Csomor, András Matolcsy, Zsolt Lengyel, Klára Petri, István Gaudi and András Rosta

Coiffier, B., Lepage, E., Briere, J. és mtsai: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 2002, 346 , 235–242. Briere J

Open access

Schulz, H., Bohlius, J. F., Trelle, S. és mtsai: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl. Cancer. Inst., 2007, 99 , 706

Restricted access
Authors: Béla Telek, Péter Batár, László Váróczy, Lajos Gergely, László Rejtő, Róbert Szász, Zsófia Miltényi, Zsófia Simon, Miklós Udvardy and Árpád Illés

.: Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br. J. Haematol., 2009, 147 , 677–680. Heffner L. T

Restricted access
Authors: Balázs Nemes, Réka P. Szabó, László Bidiga, Károly Kalmár Nagy, Lóránt Illésy and Anikó Szilvási

. 60 Okada M, Watarai Y, Iwasaki K, et al. Favorable results in AB0-incompatible renal transplantation without B cell-targeted therapy: advantages and disadvantages of rituximab pretreatment. Clin

Open access
Authors: Renáta Nyilas, Borbála Székely, László Váróczy, Zsófia Simon, Anita Árokszállási, Árpád Illés and Lajos Gergely

–167. Barcellini, W., Zaja, F., Zaninoni, A., et al.: Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood, 2012, 119 (16), 3691–3697. Barcellini, W

Restricted access